Bipartisan Senate CBD bill introduced A US Senate bill to specifically allow the use of CBD and other hemp derivatives in dietary supplements and foods has been introduced with bipartisan sponsorship. The bill also enjoys broad support within the industry.
The bill was introduced today by US Sens. Ron Wyden, D-OR, Rand Paul, R-KY and Jeff Merkley, D-OR.
FDA has ruled that CBD is not a legal dietary ingredient because it was first investigated as a drug. That drug, Epidiolex from GW Pharmaceuticals, has been approved to treat seizures in children suffering from two forms of intractable epilepsy.
FDA policing claims, but not production
Bipartisan Senate CBD bill introduced foodnavigator-usa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foodnavigator-usa.com Daily Mail and Mail on Sunday newspapers.
The ABV threshold at which kombucha switches from a non-alcoholic beverage to what is effectively beer for tax purposes is currently set at 0.5%. The KOMBUCHA Act, set to be reintroduced to Congress this session, provided the right tax vehicle comes along, would raise that threshold to 1.25% ABV.
Representative Earl Blumenauer (D-OR-3) and Senator Ron Wyden (who is now chair of the Senate Finance Committee), aim to reintroduce
“
The Congressman does plan to re-introduce the legislation this Congress, though exact timing is still to be determined,” said Rep. Blumenauer’s office, while Sen Wyden s office told us:
He is planning to introduce the bill again.
PolitiFact s ruling: True
Here s why: More than 7 million Americans require insulin to treat their diabetes but some people struggle to afford the cost.
On Jan. 14, 2021, Sen. Chuck Grassley, R-Iowa, tweeted, 2day Sen Wyden & I released Finance Cmte report on INSULIN costs Prices hv gone THRU THE ROOF for patients/taxpayers bc of manufacturer, health plan & PBM biz practices They make $$ as % of ballooning list price so no incentive to lower price on 100 yr old drug.
Grassley has a history of attempting to lower the cost of the drug, and Sen. Ron Wyden, D-Oregon, worked with him as the ranking minority member on the Senate Finance Committee when Republicans controlled the Senate.